View Section: Valuation

Lineage Cell Therapeutics Financials

Income Statement

Revenue

-N/A

‌

Growth Rates:

1 yearN/A

3 yearsN/A

5 yearsN/A

Operating income

-N/A

‌

Growth Rates:

1 yearN/A

3 yearsN/A

5 yearsN/A

Net income

-N/A

‌

Growth Rates:

1 yearN/A

3 yearsN/A

5 yearsN/A

Revenue analysis

‌

100%

Balance Sheet

Assets

Equity

‌

Cash and equivalents

Debt

‌

Financial Position Analysis

‌

Cash Flow Statement

Free Cash Flow To Equity

-N/A

‌

Growth Rates:

1 yearN/A

3 yearsN/A

5 yearsN/A

Cash Flow From Operating Activities

-N/A

‌

Growth Rates:

1 yearN/A

3 yearsN/A

5 yearsN/A

Lineage Cell Therapeutics fundamental analysis for trailing twelve months (TTM)

Gross Margin

‌

Average:

1 year0%

3 years0%

5 years0%

Operating margin

‌

Average:

1 year0%

3 years0%

5 years0%

Net Profit Margin

‌

Average:

1 year0%

3 years0%

5 years0%

Earnings quality

‌

Average:

1 year0%

3 years0%

5 years0%

Solvency Indicators

CFO / Debt ratio

‌

Average:

1 year0

3 years0

5 years0

Current ratio

‌

Average:

1 year0

3 years0

5 years0

Debt / Equity ratio

‌

Average:

1 year0

3 years0

5 years0

Efficiency Indicators

ROE

‌

Average:

1 year0%

3 years0%

5 years0%

ROIC

‌

Average:

1 year0%

3 years0%

5 years0%

ROA

‌

Average:

1 year0%

3 years0%

5 years0%

Financial Leverage

‌

Average:

1 year0

3 years0

5 years0

Dupont Analysis

Asset turnover

0.06

Financial Leverage

1.537

Stability Indicators

Net income growth rate

‌

Average growth rate (2y)

Growth rate volatility (2y)

‌

Average growth rate (5y)

Growth rate volatility (5y)

‌

View Section: Income Statement